Advertisement

Immune responses in liver-directed lentiviral gene therapy

  • Andrea Annoni
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy
    Search for articles by this author
  • Kevin Goudy
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy
    Search for articles by this author
  • Mahzad Akbarpour
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy

    Vita-Salute San Raffaele University, Milan, Italy
    Search for articles by this author
  • Luigi Naldini
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy

    Vita-Salute San Raffaele University, Milan, Italy
    Search for articles by this author
  • Maria Grazia Roncarolo
    Correspondence
    Reprint requests: Maria Grazia Roncarolo, MD, San Raffaele Telethon Institute for Gene Therapy, Via Olgettina, 58, Milan, Italy 20132
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy

    Vita-Salute San Raffaele University, Milan, Italy
    Search for articles by this author
Published:January 28, 2013DOI:https://doi.org/10.1016/j.trsl.2012.12.018
      The use of lentiviral vectors (LV)s for in vivo gene therapy is an ideal platform for treating many types of disease. Since LVs can transduce a wide array of cells, support long-term gene expression, and be modified to enhance cell targeting, LVs are a powerful modality to deliver life-long therapeutic proteins. A major limitation facing the use of LVs for in vivo gene therapy is the induction of immune responses, which can reduce the transduction efficiency of LV, eliminate the transduced cells, and inhibit the effect of the therapeutic protein. LV strategies designed to restrict transgene expression to the liver to exploit its naturally tolerogenic properties have proven to significantly reduce the induction of pathogenic immune responses and increase therapeutic efficacy. In this review, we outline the immunological hurdles facing in vivo LV gene therapy and highlight the advantages and limitations of using liver-directed LV gene therapy.

      Abbreviations:

      APC (antigen presenting cell), FoxP3 (forkhead box P3), IL (interleukin), KC (Kupffer cells), LSEC (Liver sinusoidal endothelial cells), LV (lentiviral vector), miR (micro-RNA), TLR (toll-like receptor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Amalfitano A.
        Utilization of adenovirus vectors for multiple gene transfer applications.
        Methods (San Diego, Calif). 2004; 33: 173-178
        • Aldhamen Y.A.
        • Seregin S.S.
        • Amalfitano A.
        Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.
        Frontiers Immunol. 2011; 2: 1-12
        • Nienhuis A.
        Development of gene therapy for blood disorders.
        Blood. 2008; 111: 4431-4444
        • Aiuti A.
        • Slavin S.
        • Aker M.
        • et al.
        Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
        Science (New York, NY). 2002; 296: 2410-2413
        • Aiuti A.
        • Cattaneo F.
        • Galimberti S.
        • et al.
        Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
        N Engl J Med. 2009; 360: 447-458
        • Mingozzi F.
        • High K.
        Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.
        Nat Rev Genetics. 2011; 12: 341-355
        • Mingozzi F.
        • High K.
        Immune responses to AAV in clinical trials.
        Curr Gene Ther. 2011; 11: 321-330
        • Manno C.S.
        • Pierce G.F.
        • Arruda V.R.
        • et al.
        Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
        Nat Med. 2006; 12: 342-347
        • Nathwani A.
        • Tuddenham E.
        • Rangarajan S.
        • et al.
        Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
        N Engl J Med. 2011; 365: 2357-2365
        • Naldini L.
        Ex vivo gene transfer and correction for cell-based therapies.
        Nat Rev Genetics. 2011; 12: 301-315
        • Kay M.
        State-of-the-art gene-based therapies: the road ahead.
        Nat Rev Genetics. 2011; 12: 316-328
        • Vigna E.
        • Naldini L.
        Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.
        J Gene Med. 2000; 2: 308-316
        • Naldini L.
        • Blomer U.
        • Gallay P.
        • et al.
        In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
        Science. 1996; 272: 263-267
        • Gilbert J.R.
        • Wong-Staal F.
        HIV-2 and SIV vector systems.
        Somat Cell Mol Genet. 2001; 26: 83-98
        • Holmes R.K.
        • Malim M.H.
        • Bishop K.N.
        APOBEC-mediated viral restriction: not simply editing?.
        Trends Biochem Sci. 2007; 32: 118-128
        • Page K.
        • Landau N.
        • Littman D.
        Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.
        J Virol. 1990; 64: 5270-5276
        • Trono D.
        HIV accessory proteins: leading roles for the supporting cast.
        Cell. 1995; 82: 189-192
        • Subbramanian R.
        • Cohen E.
        Molecular biology of the human immunodeficiency virus accessory proteins.
        J Virol. 1994; 68: 6831-6835
        • Naldini L.
        • Blomer U.
        • Gage F.
        • Trono D.
        • Verma I.
        Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
        Proc Natl Acad Sci U S A. 1996; 93: 11382-11388
        • Richardson J.
        • Kaye J.
        • Child L.
        • Lever A.
        Helper virus-free transfer of human immunodeficiency virus type 1 vectors.
        J Gen Virol. 1995; 76: 691-696
        • Saphire A.
        • Gallay P.
        • Bark S.
        Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins.
        J Proteome Res. 2006; 5: 530-538
        • Wheeler J.
        • Jones C.
        • Thorpe R.
        • Zhao Y.
        Proteomics analysis of cellular components in lentiviral vector production using Gel-LC-MS/MS.
        Proteomics Clin Appl. 2007; 1: 224-230
        • Spits H.
        • Cupedo T.
        Innate lymphoid cells: emerging insights in development, lineage relationships, and function.
        Ann Rev Immunol. 2012; 30: 647-675
        • Akira S.
        • Uematsu S.
        • Takeuchi O.
        Pathogen recognition and innate immunity.
        Cell. 2006; 124: 783-801
        • Huang X.
        • Yang Y.
        Innate immune recognition of viruses and viral vectors.
        Hum Gene Ther. 2009; 20: 293-301
        • Yoneyama M.
        • Kikuchi M.
        • Natsukawa T.
        • et al.
        The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.
        Nat Immunol. 2004; 5: 730-737
        • Kang D.-C.
        • Gopalkrishnan R.
        • Wu Q.
        • Jankowsky E.
        • Pyle A.
        • Fisher P.
        mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.
        Proc Natl Acad Sci U S A. 2002; 99: 637-642
        • Brown B.D.
        • Sitia G.
        • Annoni A.
        • et al.
        In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.
        Blood. 2007; 109: 2797-2805
        • Breckpot K.
        • Escors D.
        • Arce F.
        • et al.
        HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.
        J Virol. 2010; 84: 5627-5636
        • Agudo J.
        • Ruzo A.
        • Kitur K.
        • Sachidanandam R.
        • Blander J.
        • Brown B.
        A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade.
        Mol Ther. 2012; 12: 2257-2267
        • Fonteneau J.-F.
        • Larsson M.
        • Beignon A.-S.
        • et al.
        Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.
        J Virol. 2004; 78: 5223-5232
        • Beignon A.S.
        • McKenna K.
        • Skoberne M.
        • et al.
        Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.
        J Clin Invest. 2005; 115: 3265-3275
        • Rossetti M.
        • Gregori S.
        • Hauben E.
        • et al.
        HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells.
        Hum Gene Ther. 2011; 22: 177-188
        • Pichlmair A.
        • Diebold S.S.
        • Gschmeissner S.
        • et al.
        Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.
        J Virol. 2007; 81: 539-547
        • DePolo N.
        • Reed J.
        • Sheridan P.
        • et al.
        VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.
        Mol Ther. 2000; 2: 218-222
        • Guibinga G.
        • Friedmann T.
        Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.
        Mol Ther. 2005; 11: 645-651
        • Schauber-Plewa C.
        • Simmons A.
        • Tuerk M.J.
        • Pacheco C.D.
        • Veres G.
        Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation.
        Gene Ther. 2005; 12: 238-245
        • O'Shea J.
        • Paul W.
        Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells.
        Science (New York, NY). 2010; 327: 1098-1102
        • Gromme M.
        • Neefjes J.
        Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.
        Mol Immunol. 2002; 39: 181-202
        • Lopes L.
        • Fletcher K.
        • Ikeda Y.
        • Collins M.
        Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
        Cancer Immunol Immunother CII. 2006; 55: 1011-1016
        • Zarei S.
        • Abraham S.
        • Arrighi J.-F.
        • et al.
        Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo.
        J Virol. 2004; 78: 7843-7845
        • Abordo-Adesida E.
        • Follenzi A.
        • Barcia C.
        • et al.
        Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.
        Hum Gene Ther. 2005; 16: 741-751
        • Mingozzi F.
        • Maus M.V.
        • Hui D.J.
        • et al.
        CD8(+) T-cell responses to adeno-associated virus capsid in humans.
        Nat Med. 2007; 13: 419-422
        • Rowe H.
        • Lopes L.
        • Ikeda Y.
        • et al.
        Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
        Mol Ther. 2006; 13: 310-319
        • Follenzi A.
        • Battaglia M.
        • Lombardo A.
        • Annoni A.
        • Roncarolo M.G.
        • Naldini L.
        Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.
        Blood. 2004; 103: 3700-3709
        • Annoni A.
        • Battaglia M.
        • Follenzi A.
        • et al.
        The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells.
        Blood. 2007; 110: 1788-1796
        • Stein C.
        • Kang Y.
        • Sauter S.
        • et al.
        In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors.
        Mol Ther. 2001; 3: 850-856
        • Matsui H.
        • Hegadorn C.
        • Ozelo M.
        • et al.
        A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
        Mol Ther. 2011; 19: 723-730
        • Di Domenico C.
        • Di Napoli D.
        • Gonzalez Y.
        • et al.
        Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
        Hum Gene Ther. 2006; 17: 1112-1121
        • Saenko E.
        • Shima M.
        • Gilbert G.
        • Scandella D.
        Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
        J Biol Chem. 1996; 271: 27424-27431
        • Fehervari Z.
        • Sakaguchi S.
        CD4 Tregs and immune control.
        J Clin Invest. 2004; 114: 1209-1217
        • Sakaguchi S.
        • Yamaguchi T.
        • Nomura T.
        • Ono M.
        Regulatory T cells and immune tolerance.
        Cell. 2008; 133: 775-787
        • Haribhai D.
        • Williams J.
        • Jia S.
        • et al.
        A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity.
        Immunity. 2011; 35: 109-122
        • Curotto de Lafaille M.
        • Lafaille J.
        Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?.
        Immunity. 2009; 30: 626-635
        • Gregori S.
        • Goudy K.
        • Roncarolo M.
        The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells.
        Frontiers Immunol. 2012; 3: 30
        • Chen W.
        • Jin W.
        • Hardegen N.
        • et al.
        Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
        J Exp Med. 2003; 198: 1875-1886
        • Kretschmer K.
        • Apostolou I.
        • Hawiger D.
        • Khazaie K.
        • Nussenzweig M.C.
        • von Boehmer H.
        Inducing and expanding regulatory T cell populations by foreign antigen.
        Nat Immunol. 2005; 6: 1219-1227
        • Apostolou I.
        • von Boehmer H.
        In vivo instruction of suppressor commitment in naive T cells.
        J Exp Med. 2004; 199: 1401-1408
        • Gross D.A.
        • Leboeuf M.
        • Gjata B.
        • Danos O.
        • Davoust J.
        CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection.
        Blood. 2003; 102: 4326-4328
        • Cao O.
        • Dobrzynski E.
        • Wang L.
        • et al.
        Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.
        Blood. 2007; 110: 1132-1140
        • Luth S.
        • Huber S.
        • Schramm C.
        • et al.
        Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs.
        J Clin Invest. 2008; 118: 3403-3410
        • Annoni A.
        • Brown B.D.
        • Cantore A.
        • Sergi Sergi L.
        • Naldini L.
        • Roncarolo M.G.
        In vivo delivery of a microRNA regulated transgene induces antigen-specific regulatory T cells and promotes immunological tolerance.
        Blood. 2009; 114: 5152-5161
        • Crispe I.N.
        Hepatic T cells and liver tolerance.
        Nat Rev Immunol. 2003; 3: 51-62
        • Warren A.
        • Le Couteur D.G.
        • Fraser R.
        • Bowen D.G.
        • McCaughan G.W.
        • Bertolino P.
        T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells.
        Hepatology. 2006; 44: 1182-1190
        • Bertolino P.
        • Trescol-Biemont M.C.
        • Thomas J.
        • et al.
        Death by neglect as a deletional mechanism of peripheral tolerance.
        Int Immunol. 1999; 11: 1225-1238
        • Knolle P.A.
        • Germann T.
        • Treichel U.
        • et al.
        Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells.
        J Immunol. 1999; 162: 1401-1407
        • Limmer A.
        • Ohl J.
        • Kurts C.
        • et al.
        Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance.
        Nat Med. 2000; 6: 1348-1354
        • Knolle P.A.
        • Limmer A.
        Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells.
        Trends Immunol. 2001; 22: 432-437
        • Knolle P.
        • Schlaak J.
        • Uhrig A.
        • Kempf P.
        Meyer zum B√°schenfelde K, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge.
        J Hepatol. 1995; 22: 226-229
        • Knolle P.
        • Uhrig A.
        • Protzer U.
        • et al.
        Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells.
        Hepatology (Baltimore, Md). 1998; 27: 93-99
        • Mocellin S.
        • Panelli M.
        • Wang E.
        • Nagorsen D.
        • Marincola F.
        The dual role of IL-10.
        Trends Immunol. 2003; 24: 36-43
        • Bissell D.
        • Wang S.
        • Jarnagin W.
        • Roll F.
        Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.
        J Clin Invest. 1995; 96: 447-455
        • Huang L.
        • Soldevila G.
        • Leeker M.
        • Flavell R.
        • Crispe I.
        The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo.
        Immunity. 1994; 1: 741-749
        • Bertolino P.
        • Trescol-Biemont M.C.
        • Rabourdin-Combe C.
        Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival.
        Eur J Immunol. 1998; 28: 221-236
        • Benseler V.
        • Warren A.
        • Vo M.
        • et al.
        Hepatocyte entry leads to degradation of autoreactive CD8 T cells.
        Proc Natl Acad Sci U S A. 2011; 108: 16735-16740
        • Martino A.
        • Nayak S.
        • Hoffman B.
        • et al.
        Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity.
        PloS One. 2009; 4: e6376
        • Breous E.
        • Somanathan S.
        • Vandenberghe L.
        • Wilson J.
        Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver.
        Hepatology (Baltimore, Md). 2009; 50: 612-621
        • Knolle P.A.
        • Schmitt E.
        • Jin S.
        • et al.
        Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells.
        Gastroenterology. 1999; 116: 1428-1440
        • Wiegard C.
        • Frenzel C.
        • Herkel J.
        • Kallen K.-J.
        • Schmitt E.
        • Lohse A.
        Murine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells.
        Hepatology (Baltimore, Md). 2005; 42: 193-199
        • Knolle P.
        • Gerken G.
        Local control of the immune response in the liver.
        Immunol Rev. 2000; 174: 21-34
        • LoDuca P.A.
        • Hoffman B.E.
        • Herzog R.W.
        Hepatic gene transfer as a means of tolerance induction to transgene products.
        Curr Gene Ther. 2009; 9: 104-114
        • Kobayashi H.
        • Carbonaro D.
        • Pepper K.
        • et al.
        Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
        Mol Ther. 2005; 11: 776-789
        • Nguyen T.
        • Bellodi-Privato M.
        • Aubert D.
        • et al.
        Therapeutic lentivirus-mediated neonatal in vivo gene therapy in hyperbilirubinemic Gunn rats.
        Mol Ther. 2005; 12: 852-859
        • Schmitt Fo
        • Remy Sv
        • Dariel A.
        • et al.
        Lentiviral vectors that express UGT1A1 in liver and contain miR-142 target sequences normalize hyperbilirubinemia in Gunn rats.
        Gastroenterology. 2010; 139: 999
        • Waddington S.
        • Nivsarkar M.
        • Mistry A.
        • et al.
        Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy.
        Blood. 2004; 104: 2714-2721
        • Cao O.
        • Hoffman B.
        • Moghimi B.
        • et al.
        Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.
        Mol Ther. 2009; 17: 1733-1742
        • Markusic D.
        • van Til N.
        • Hiralall J.
        • Elferink R.
        • Seppen J.
        Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain.
        BMC Biotechnol. 2009; 9: 85
        • Kang Y.
        • Xie L.
        • Tran D.
        • et al.
        Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
        Blood. 2005; 106: 1552-1558
        • Brown B.
        • Naldini L.
        Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications.
        Nat Rev Genetics. 2009; 10: 578-585
        • Brown B.D.
        • Venneri M.A.
        • Zingale A.
        • Sergi Sergi L.
        • Naldini L.
        Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.
        Nat Med. 2006; 12: 585-591
        • Brown B.D.
        • Cantore A.
        • Annoni A.
        • et al.
        A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice.
        Blood. 2007; 110: 4144-4152
        • Matrai J.
        • Cantore A.
        • Bartholomae C.C.
        • et al.
        Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk.
        Hepatology. 2011; 53: 1696-1707
        • Ward N.
        • Buckley S.
        • Waddington S.
        • et al.
        Codon optimization of human factor VIII cDNAs leads to high-level expression.
        Blood. 2011; 117: 798-807
        • Bielicki J.
        • McIntyre C.
        • Anson D.
        Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.
        Mol Genetics Metab. 2010; 101: 370-382
        • McIntyre C.
        • Derrick Roberts A.
        • Ranieri E.
        • Clements P.
        • Byers S.
        • Anson D.
        Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
        Mol Genetics Metab. 2008; 93: 411-418
        • Seppen J.
        • van Til N.
        • van der Rijt R.
        • Hiralall J.
        • Kunne C.
        • Elferink R.
        Immune response to lentiviral bilirubin UDP-glucuronosyltransferase gene transfer in fetal and neonatal rats.
        Gene Ther. 2006; 13: 672-677
        • van der Wegen P.
        • Louwen R.
        • Imam A.
        • et al.
        Successful treatment of UGT1A1 deficiency in a rat model of Crigler-Najjar disease by intravenous administration of a liver-specific lentiviral vector.
        Mol Ther. 2006; 13: 374-381